ATRS:NSD-Antares Pharma, Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 4.26

Change

-0.12 (-2.74)%

Market Cap

USD 0.74B

Volume

0.80M

Avg Analyst Target

USD 7.00 (+64.32%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and for glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto injectors; and drug/device product for urologic oncology and endocrinology. The company have strategic alliances and partnership arrangements pharmaceutical companies, including Pfizer, Idorsia, Teva, and AMAG. Antares Pharma, Inc. was founded in 1978 and is headquartered in Ewing, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-04 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical, Inc

-8.73 (-0.87%)

USD118.70B 74.64 59.37
HOLX Hologic, Inc

+0.85 (+1.12%)

USD19.20B 9.70 7.00
NVCR NovoCure Limited

+3.97 (+2.66%)

USD15.46B 1,480.87 623.21
MASI Masimo Corporation

+2.57 (+0.93%)

USD15.25B 71.72 49.95
XRAY DENTSPLY SIRONA Inc

-1.04 (-1.59%)

USD14.26B 83.02 26.94
RGEN Repligen Corporation

+3.52 (+1.41%)

USD13.69B 138.45 85.70
STAA STAAR Surgical Company

+0.90 (+0.70%)

USD6.00B 578.51 314.88
ICUI ICU Medical, Inc

-0.47 (-0.25%)

USD4.06B 44.17 19.44
ATRC AtriCure, Inc

-1.64 (-1.96%)

USD3.81B N/A N/A
MMSI Merit Medical Systems, Inc

-1.68 (-2.48%)

USD3.79B 135.36 112.14

ETFs Containing ATRS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.77% 52% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.77% 52% F 50% F
Trailing 12 Months  
Capital Gain 42.00% 52% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.00% 52% F 61% D-
Trailing 5 Years  
Capital Gain 287.27% 60% D- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 287.27% 60% D- 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 19.73% 41% F 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.73% 41% F 65% D
Risk Return Profile  
Volatility (Standard Deviation) 40.85% 66% D 44% F
Risk Adjusted Return 48.29% 48% F 67% D+
Market Capitalization 0.74B 47% F 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 12.34 83% B 63% D
Price/Book Ratio 5.95 43% F 25% F
Price / Cash Flow Ratio 34.68 38% F 13% F
EV/EBITDA 31.86 50% F 27% F
Management Effectiveness  
Return on Equity 69.27% 97% A+ 98% A+
Return on Invested Capital 47.00% 97% A+ 96% A
Return on Assets 7.17% 74% C 88% B+
Debt to Equity Ratio 20.71% 39% F 59% F
Technical Ratios  
Short Ratio 5.10 28% F 24% F
Short Percent 2.91% 59% F 53% F
Beta 1.46 27% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.